Retatrutide + Cagrilintide
Retatrutide + Cagrilintide is a weekly research vial of retatrutide (a GIP / GLP-1 / glucagon receptor agonist) and cagrilintide (an amylin analog): 10 mg + 2 mg in a 12 mg vial mixed with 1 mL of water, or 20 mg + 4 mg in a 24 mg vial mixed with 2 mL.
Dosed in insulin units on retatrutide's own weekly steps: 10 units (retatrutide 1 · cagrilintide 0.2 mg), 20, 40 and 80 units, topping out at 85 units (8.5 · 1.7 mg). It is not CagriSema.
Best for
Weight-management research interest in pairing a triple incretin agonist with an amylin analog. Neither compound is approved, and no human trial has tested the pair.
What to expect
Each compound's trials measured weight change over months (26 weeks for cagrilintide, 48 weeks for retatrutide); the only study of the two together was in rats.
Pairs with
Already an incretin plus an amylin analog: do not add a GLP-1-class drug (retatrutide, tirzepatide, semaglutide) or a second amylin agonist (cagrilintide, eloralintide) on top of it.
Once weekly, under the skin, in the morning. Mix a 12 mg vial with 1 mL of water or a 24 mg vial with 2 mL — either way each unit is 0.1 mg retatrutide + 0.02 mg cagrilintide.
The ladder follows retatrutide's weekly steps: 10 units (1 mg + 0.2 mg), 20 (2 + 0.4), 40 (4 + 0.8) and 80 (8 + 1.6), with 85 units (8.5 + 1.7) as the top, where cagrilintide reaches its own 1.7 mg top. Step up no faster than every 4 weeks, and only if progress has stalled — the ladder is a ceiling, not a schedule.
Specific dosing varies by goal and physician guidance.
- How often
- Weekly
- When
- Morning
- Route
- Subcutaneous
- Vial & water
- 12 mg in 1 mL · 10 units ≈ 1 mg Retatrutide + 0.2 mg Cagrilintide
- Cycle
- Units, weekly: 10 → 20 → 40 → 80 → 85 u, no faster than every 4 weeks, and only if your response has stalled.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
No approved brand anywhere. Neither compound is approved, and no human trial has tested them together — this pairing is not CagriSema (which is cagrilintide with semaglutide).
Retatrutide is an investigational single peptide that activates three receptors — GIP, GLP-1 and glucagon; its phase 2 obesity trial gave 1–12 mg once a week for 48 weeks. Cagrilintide is a long-acting amylin analog; its phase 2 dose-finding trial gave 0.3–4.5 mg once a week.
The pairing rests on complementary appetite pathways (incretin and amylin), the same rationale as CagriSema (cagrilintide with semaglutide). The only published study of retatrutide with cagrilintide gave them to obese male rats; no human study exists, and neither compound is approved.
References3
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (N Engl J Med) (retatrutide 1-12 mg weekly)
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (Lancet) (cagrilintide 0.3-4.5 mg weekly)
- Petersen J et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats (Nat Metab) (the combination, in rats)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.